4 December 2018 / Ottignies-Louvain-la-Neuve, Belgium

Agenda

The event agenda's time zone is CET.

Tue
4 Dec 2018
08:30 – 09:15
Doors Opening
09:15 – 09:30
Welcome Speech

Welcome from Philippe Denoël, Chairman of BioWin and Director, External R&D at GlaxoSmithKline Biologicals and Sylvie Ponchaut, Managing Director at BioWin

09:30 – 10:10
Plenary 1 - Avatars, Humans and Machines

Miladus Doueihi, Professor and Chairman of Digital Humanism, Paris Sorbonne, France

A brief history of creativity and intelligence from the early period of computing to our contemporary environment. What are some of the most striking features shaping our perceptions of machines as they gain more acceptance and especially more autonomy? From Alan Turing, Norbert Wiener and the ways in which they transformed our cultural landscape to current debates focusing on the diversity of forms artificial intelligence can take and its deployment across various sectors and cultural zones, we will focus on the relationships between humans and their “digital angels”, visiting, along the way, technical, legal and ethical concerns that are certain to remain with us for the foreseeable future.

10:10 – 10:50
Plenary 2 - The two AIs, conscious and unconscious

Hugues Bersini, Professor at the Université Libre de Bruxelles, member of the Belgium Royal Academy of Sciences, Belgium

Since the birth of AI 60 years ago, two R&D directions have been in competition: the conscious, symbolic and overt AI, giving rise to software for planning, problem solving, expert systems; and the unconscious and covert AI, based on neural networks, machine learning and big data.  Depending on the relative success or failure of these two types of AI in overtaking human cognitive performance, they have alternated in being under the spotlight. We will explain the history and the reasons for these two scientific directions and why, currently, the second direction, re-named as Deep Learning and Big Data (old wine in a new bottle) has gained a huge amount of attention.


10:50 – 11:20
Coffee Break and Networking Opportunity
11:20 – 12:00
Plenary 3 - Big data, machine learning and medicine by numbers!

Jacques Corbeil, Professor of Medicine, Department of Molecular Medicine, Université Laval, Canada

How can we use big data and machine learning algorithms to assist in medical decision making? We will provide a few examples of the use of machine learning arising from our experience with the analysis of sequencing and mass spectrometry data obtained from patients and healthy cohorts. There are numerous opportunities to use machine learning in medicine, especially by using supervised and sparse methods. These opportunities have the great advantage of being interpretable which is a key criterion for their acceptability. 

12:00 – 13:00
Plenary 4 - Successful integration of AI in the healthcare business

Addressing the complexity of life sciences mechanisms and the digital « garbage in garbage  out » reality through CADI™ Discovery

Manuel Gea, CEO and co-founder at Bio-Modeling Systems, Belgium

Bio-Modeling Systems is the world’s first Mechanisms-Based Medicine company that successfully changed the discovery paradigm. We propose to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses. Created in 2004, profitable since 2006, thanks to our recurrent clients, key achievements of CADI™ Discovery (Computer Augmented Deductive Intelligence) will be presented.

How 3D Simulation and Clinical Decision Support System will transform the planning and execution of orthopedic surgeries and treatments

Eric Halioua, CEO of Digital Orthopedics, Belgium

Digital Orthopaedics ambition is to transform and improve patient treatment and outcome by providing Health Care Professionals, surgeons and medical device companies with a state-of-the-art Clinical Decision and Surgical Simulation Support Systems for musculoskeletal pathologies. The company assist: 1) orthopedic surgeons involved in the treatment of foot & ankle pathologies to identify the optimum treatment and surgical therapeutic plan for each patient; 2) device companies with a mechanism for virtual clinical studies for testing implants and prosthetic ankles.

Radiomics: a non-invasive, 3D, AI-based biomarkers for Precision Medicine

Philippe Lambin, CSO, co-founder and member of the Board at Oncoradiomics, Belgium

In the last 5 years, accumulating evidence has indicated that AI-based non-invasive advanced imaging analytics, the so-called “Radiomics” approach, can reveal key components of tumor phenotype or even genotype for multiple lesions at multiple time points over the course of treatment. The goal of this approach is the development of actionable diagnostic or prediction models that will yield meaningful applications of precision medicine in general.



12:30 – 14:00
Networking Lunch
  • In parallel to Plenary 4
  • In parallel to B2B Meetings I
13:00 – 14:00
B2B Meetings - Session I
  • 3 Meetings max during this session
  • In parallel to Networking Lunch
Matchmaking
14:00 – 15:30
CFO Meeting (Private Satellite Meeting)

Moderators:

Sandra Cauwenberghs, Senior Financial Analyst, Pharma & Biotech at KBC Securities, Belgium

Michaël Vlemmix, Associate, Health & Care at Gimv, Belgium

14:00 – 15:30
Workshop 1 - AI & diagnostics: potential and current limits

Different aspects of AI integration in diagnostics will be debated. Representative stakeholders will bring specific insights in areas including medical imaging and the identification and validation of biomarkers, and in the global challenges linked to collecting, handling and mining of health data relevant for diagnostics, prognostics and theranostics.

Moderator:

Jacques Corbeil, Professor of Medicine, Department of Molecular Medicine, Université Laval, Canada

Guest speakers:

Thibault Helleputte, Co-founder and CEO at DNAlytics, Belgium

François Nicolas, Chief Digital Officer at Guerbet, France

***

  • In parallel to the two other Workshops
  • In parallel to B2B Meetings II
Workshop
14:00 – 15:30
Workshop 2 - Health data bases for innovation and improving healthcare

Health data bases are considered as an important data source to assist research, and the development of preventative (prophylactic) and innovative medicines. During this workshop, two recently launched Belgian initiatives: “Data for better Health” and “INAH”. A particular attention will be paid on legal, ethical and intellectual property questions raised by the use of these data bases.

Moderator:

Alain Wouters, Managing Director at Whole Systems, Belgium

Guest Speakers:

Damien Hubaux, Managing Director at CETIC, Belgium, on behalf of INAH (Institute of Analytics for Health)

Johan Van Bussel, Head of Heathdata.be at Sciensano, Belgium, on behalf of Data for better health

Jean-Marc Van Gyseghem, Director of Research at CRIDS, Université de Namur, Belgium, as legal expert

Valérie Kokoszka, Lecturer/professor-researcher at Centre d’Ethique Médicale, Université de Lille, France, as ethical expert

Caroline de Mareüil-Villette, Founding Partner ICOSA Europe, Belgium, as intellectual property expert

***

  • In parallel to the two other Workshops
  • In parallel to B2B Meetings II


Workshop
14:00 – 15:30
Workshop 3 - When Big Pharma meet Big Data

Big Pharma representatives will share their experience of the integration of AI in their current strategies and activities. Together with entities involved in AI development and implementation, they will sketch out an overview of the future potential of AI in applications such as drug discovery and drug development, biomanufacturing, disease modelling, data analytics and clinical trials.

Moderator:

Rodolphe Lebrun, Director Strategy, Customer & Operations at KPMG, Belgium

Guest speakers: 

Bart Vannieuwenhuyse, Senior Director Health Information Sciences at Janssen Pharmaceutica, Belgium
Nassim Haddad, Director IT, Head of IT advanced analytics at UCB, Belgium
Erik Doffagne, Product Manager at IDDI, Belgium
Roel Wuyts, Team Lead "ExaScience Life Lab" at imec, Belgium
Jonathan Wagg, Disease Therapeutic Area Modeling Leader – Oncology at Roche, Clinical Pharmacology-Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland

***

  • In parallel to the two other Workshops
  • In parallel to B2B Meetings II


Workshop
14:10 – 15:30
B2B Meetings - Session II
  • 4 Meetings max during this session
  • In parallel to Workshops
Matchmaking
15:30 – 16:00
Break - Networking


  • In parallel to B2B Meetings III
15:35 – 15:55
B2B Meetings - Session III

  • 1 Meeting max during this session
  • In parallel to Break
Matchmaking
16:00 – 17:00
B2B Meetings - Session IV

  • 3 Meetings max during this session
  • In parallel to Panels
Matchmaking
16:00 – 16:45
Plenary 5 - imec

Jo De Boeck, Chief Technology Officer and Excecutive Vice President at imec, Belgium

16:45 – 17:00
Plenary 6 - European vision

Karim Berkouk, Directorate-General for Research & Innovation at European Commission, Belgium


17:00 – 17:50
Panel

Join the exciting debate between Belgian and international experts who will explore the legal, ethical and policy implications of AI.
The debate will also focus on the impact of AI on employment and training.
Be part of this concluding session which can be guaranted to provide tons of food for thought.

Moderator:

Ingmar de Gooijer, Director Public Policy & Reimbursement at myTomorrows, The Netherlands

Guest speakers:

Hugues Bersini, Professor at the Université Libre de Bruxelles, member of the Belgium Royal Academy of Sciences, Belgium
Jacques Corbeil, Professor of Medicine, Department of Molecular Medicine, Université Laval, Canada
Manuel Gea, CEO and Co-founder of Bio-Modeling Systems, France
Karim Berkouk, Directorate-General for Research & Innovation at European Commission, Belgium
Jean-Marc Van Gyseghem, Director of Research at CRIDS, Université de Namur, Belgium

***

  • In parallel to B2B Meetings IV


17:50 – 18:00
Conclusions

Sylvie Ponchaut, Managing Director at BioWin

18:00 – 20:00
Walking Dinner - Networking
The event agenda's time zone is CET.